The more I think about this and the more I read the more convinced I become that the Immunotherapies division should be spun off and left to fend for itself. I don't want it dragging down the rest of the business any further.
Thinking about the timeline I've been watching this for now (3 years?) and the immunotherapies has loomed large over the SP for that entire time. People are obsessed with it and this SP isn't going anywhere fast without clear separation between the grounded working Medical Devices and CC are doing, and the blue sky vaccine.
Ann: Admedus Releases Results of HSV-2 Phase IIa Study, page-313
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.60 |
Change
-0.100(0.53%) |
Mkt cap ! $357.5M | |||
| Open | High | Low | Value | Volume |
| $18.70 | $18.77 | $18.21 | $664.1K | 35.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $18.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.69 | 53 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |